M&A / Deals Gilead outlays $5bn to acquire ADC specialist Tubulis Pharmaceutical TechnologySixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.M&A / DealsRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) Pharmaceutical Technology Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs. M&A / DealsRead full story Post navigation Previous: Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist TubulisNext: Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
